The global medical psychedelics and cannabis industries ars experiencing notable growth, marked by numerous international jurisdictions progressing toward the establishment of clinical services. In 2023 Australia found itself at the forefront of this trend, having recently rescheduled MDMA and psilocybin, thereby facilitating the establishment of clinics across the country.

​​

CAPS specializes in offering consultation and advisory services to individuals, companies, clinics, and investment organizations engaged in developing psychedelic clinical services in the UK, Europe, and worldwide. 

​

With experience as a prescriber in the UK medical cannabis industry, CAPS can also advise professionals in this field.

​​

It is important to note that CAPS does not offer medical advice or assume clinical responsibility for specific clinical cases.